OUST · Ouster, Inc. · Stock research

Current Thesis

The second parabolic leg ran, and then the company sold into it. On 2026-07-02 management priced a 3,621,876-share underwritten offering at $55.22 — an ~8% discount to the $60.02 prior close — closing 2026-07-06 for ~$191.9M net. The tape has since given the entire move back: $37.04 on 2026-07-17, about 42% under the high, below both the 20-day (~$46.40 as of 2026-07-10) and the 50-day, and now trading beneath the $49.00 average analyst target it had spent June above. The lidar-for-Physical-AI story is intact and the balance sheet is materially stronger. The squeeze that priced it is over, and there is no repaired base yet.

Bullish and bearish views on Ouster, Inc.

The model's bull view on Ouster, Inc. (OUST), in brief: Funded, and no longer a going-concern debate. The bear view: The prior structural line has already failed. Both cases follow in full.

Bull Case

• Funded, and no longer a going-concern debate. The 2026-07-06 offering added ~$191.9M net at a price the market has not seen since. For an unprofitable sensor manufacturer scaling a contract-manufacturing ramp, buying that capital at $55.22 was opportunistic execution.
• Revenue growth is genuine and sustained. Q1 2026 (2026-05-05): total revenue $48.58M, +49% YoY; product revenue a record $48.23M, +55% YoY; 13 consecutive quarters of product-revenue growth. TTM revenue $185.33M, +57.3%.
• Regulatory moat widened. Rev8 BABA compliance (early July 2026) opens federally funded infrastructure procurement — the exact channel BlueCity sells into, where non-compliant foreign lidar is disqualified rather than merely disfavoured.
• Verticals are broadening past robotaxi. AIM Intelligent Machines (2026-06-17) puts Rev8 native-colour sensors into autonomous mining, construction and defence fleets; Benchmark (2026-06-15) supplies the volume path; BlueCity runs at 40+ New Jersey highway sites into the 2026 FIFA World Cup against a contracted base reported above 700 sites.
• Sell-side kept raising into the drawdown. Oppenheimer maintained Outperform and lifted its target to $57 from $42 on 2026-07-15 — after the offering, with the stock in the high $30s. Consensus across 7 analysts is Strong Buy, average target $49.00, with Roth/MKM at $75 and Rosenblatt at $53.

Bear Case

• The prior structural line has already failed. The $40 shelf that held the early-June air pocket broke in July. Price closed the week of 2026-07-17 at $37.04 after tagging $33.08 intraday, which erases the June higher low and the May breakout base in one leg.
• An issuer-timed top. Pricing 5.6% of the share count at an 8% discount two days after a 52-week high is the clearest possible statement about where management thought the stock was. Share count is now 67.29M.
• Dilution came on top of an existing lid. The $100M ATM sales agreement dated 2026-05-08 remains available alongside the completed offering, so supply is not exhausted.
• Still loss-making, still margin-pressured. TTM net income -$55.83M. Q1 GAAP gross margin fell to ~43% from ~60% QoQ; Q2 margin guidance was only 35–40%. At a $2.49B cap the stock trades ~13.4x TTM sales against negative operating leverage.
• trailing-90-day insider sales totalled roughly 298,409 shares / $7.37M. No open-market purchases.
• Q2 lands on 2026-08-06 with the tape already broken. A guide-down into a wounded chart is a materially different setup from a guide-down into momentum.

Setup & Price Structure

• Price: $37.04 close 2026-07-17 (+5.41%), $36.66 after hours; prior close $35.14; 2026-07-15 close $37.95.
• 52-week range: $16.40 → $63.79. Still ~2.3x off the low, ~42% off the high.
• Moving averages: below the 20-day (~$46.40 on 2026-07-10) and the 50-day; well above the 200-day (~$28.09 on 2026-07-10, now rising). The gap between spot and the 200-day is the unresolved risk.
• Volume signature: 4.56M shares on the 2026-07-17 bounce against a heavy distribution sequence — 2026-07-07 -10.83% to $44.44, 2026-07-10 -6.99% to $44.21, then a further slide into the $33 handle. Down days carried the weight.
• Level map: $33.08 is the July capitulation low and the first reference. $40 is now overhead resistance rather than support. $44–46 is the offering-aftermath supply shelf and the 20-day. $55.22 is the offering print, where a large tranche of new holders sits underwater.
• Character: low-float former-SPAC with meme history, capable of ±16% single sessions on undated press releases. Position sizing on this name belongs in probe territory regardless of conviction.

Catalyst Calendar (next 30 days)

• Late July 2026 (est.) — bi-monthly short-interest settlement update; relevant given the squeeze mechanics that drove the early-July leg.
• Ongoing, undated — Rev8 design-win and BABA-channel infrastructure announcements. These have produced double-digit single-day moves twice in two months and remain the swing factor between prints.
• No FDA/regulatory or index-rebalance events dated in the window.

Elapsed catalysts

• 2026-08-06 (confirmed) — Q2 2026 results after the close, call 5:00 p.m. ET. The first fundamental print since the raise; watch product revenue against the ~$49.5M low end, gross margin against the 35–40% guide, and any updated share count. (passed 3d ago)

What Would Change Our Mind

• Constructive re-rate: a higher low above $33 followed by a weekly close back over $46 that recovers the 20-day and the offering-aftermath shelf, ideally on a dated design win with disclosed dollar value rather than another unquantified partnership release.
• Q2 confirmation: 2026-08-06 product revenue above the guide with gross margin holding the 35–40% band and no new ATM issuance disclosed would convert a broken chart into a base worth working.
• Structural failure: a weekly close under $33 puts the 200-day near $28 in play and reframes the entire June–July sequence as a distribution top.
• Narrative failure: a Rev8 volume-ramp delay, a Benchmark scale-back, or a lost BlueCity infrastructure contract would remove the specific proof points the July move was priced on.

Correlation Notes

• Lidar complex — LAZR, INVZ, AEVA, MVIS. OUST is the revenue leader of the group and sets the tone; a sympathy bid in the loss-making peers without OUST participating usually marks the low-quality end of a squeeze.
• Physical-AI / robotics basket — SERV, and autonomy sleeves inside the megacap complex. The theme carried OUST from $16 to $63; theme drawdowns transmit here with amplified beta given the float.
• High-beta small-cap flow — behaves like a liquidity proxy. Rate-sensitive unprofitable growth de-risking hits this name before it hits the index.
• Offering-overhang cohort — names that raised into strength in July trade with the same shape: sharp discount gap, failed bounce at the pricing level, base only after the new float turns over. That comparison set is more predictive here than the lidar peers.